Pfizer has found another use for the windfall profits it is making from it BioNTech-partnered COVID-19 vaccine, agreeing to buy Arena Pharma and its late-stage ulcerative colitis drug etras
Preliminary study results from South Africa have suggested that antibodies stimulated by Pfizer and BioNTech's Comirnaty are less effective against the new COVID-19 variant Omicron.
AstraZeneca has snapped up another Ionis-discovered drug for its pipeline, this time phase 3 candidate eplontersen for the disease transthyretin amyloidosis (ATTR).
A trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body's T-cell immunity against the disease.
Bayer's Nubeqa is making headway as a treatment for castration-resistant prostate cancer (CRPC), but could be on track to expand its eligible patient population thanks to new phase 3 data.<
The UK government has placed a 114 million-dose order with Pfizer/BioNTech and Moderna – sufficient to provide two doses to every person in Britain – in a bid to future-proof against COVID-